General information | DisProt: | DP00492 | Name: | Androgen receptor [Isoform 1 (AR-B)] | Synonym(s): | ANDR_HUMAN
Dihydrotestosterone receptor
Nuclear receptor subfamily 3 group C member 4
| First appeared in release: | Release 3.2 (05/26/2006) | UniProt: | P10275-1 | UniGene: | Hs.496240 | SwissProt: | ANDR_HUMAN | TrEMBL: | | NCBI (GI): | 113830 | Source organism: | Homo sapiens (Human) | Sequence length: | 919 | Percent disordered: | 37% | Homologues: | |
Native sequence |
10 20 30 40 50 60 | | | | | | MEVQLGLGRV YPRPPSKTYR GAFQNLFQSV REVIQNPGPR HPEAASAAPP GASLLLLQQQ - 60 QQQQQQQQQQ QQQQQQQQET SPRQQQQQQG EDGSPQAHRR GPTGYLVLDE EQQPSQPQSA - 120 LECHPERGCV PEPGAAVAAS KGLPQQLPAP PDEDDSAAPS TLSLLGPTFP GLSSCSADLK - 180 DILSEASTMQ LLQQQQQEAV SEGSSSGRAR EASGAPTSSK DNYLGGTSTI SDNAKELCKA - 240 VSVSMGLGVE ALEHLSPGEQ LRGDCMYAPL LGVPPAVRPT PCAPLAECKG SLLDDSAGKS - 300 TEDTAEYSPF KGGYTKGLEG ESLGCSGSAA AGSSGTLELP STLSLYKSGA LDEAAAYQSR - 360 DYYNFPLALA GPPPPPPPPH PHARIKLENP LDYGSAWAAA AAQCRYGDLA SLHGAGAAGP - 420 GSGSPSAAAS SSWHTLFTAE EGQLYGPCGG GGGGGGGGGG GGGGGGGGGG GGEAGAVAPY - 480 GYTRPPQGLA GQESDFTAPD VWYPGGMVSR VPYPSPTCVK SEMGPWMDSY SGPYGDMRLE - 540 TARDHVLPID YYFPPQKTCL ICGDEASGCH YGALTCGSCK VFFKRAAEGK QKYLCASRND - 600 CTIDKFRRKN CPSCRLRKCY EAGMTLGARK LKKLGNLKLQ EEGEASSTTS PTEETTQKLT - 660 VSHIEGYECQ PIFLNVLEAI EPGVVCAGHD NNQPDSFAAL LSSLNELGER QLVHVVKWAK - 720 ALPGFRNLHV DDQMAVIQYS WMGLMVFAMG WRSFTNVNSR MLYFAPDLVF NEYRMHKSRM - 780 YSQCVRMRHL SQEFGWLQIT PQEFLCMKAL LLFSIIPVDG LKNQKFFDEL RMNYIKELDR - 840 IIACKRKNPT SCSRRFYQLT KLLDSVQPIA RELHQFTFDL LIKSHMVSVD FPEMMAEIIS - 900 VQVPKILSGK VKPIYFHTQ
|
Functional narrative |
The actions of androgens are mediated through the androgen receptor (AR), an intracellular receptor that belongs to the steroid nuclear receptor superfamily. The actions of male sex hormones testosterone and dihydrotestosterone are facilitated by the AR. Consisting of three domains, androgen receptor contains the ligand binding domain (LBD), the DNA binding domain (DBD), and the amino terminal domain (NTD). At the C-terminus, the LBD (amino acids 663-919) is responsible for dimerization, androgen binding, and ligand dependent transactivation. The DBD (amino acids 548-612) controls recognition of, and binding to DNA target sequences and receptor dimerization. At the amino terminal end, the NTD (amino acids 142-485) is critical for transactivation, and protein interactions with the LBD. Binding of the NTD to its target protein transcription factor (TFIIF) results in a disorder to order transition, creating more stability within the structure. The largest stretch of glutamines [within the NTD] is of particular interest because expansion of this sequence from on-average 22 to greater than 40 residues results in the neuromuscular degenerative condition spinal bulbar muscular atrophy or Kennedy's Disease. In addition, polymorphisms in this polyglutamine stretch have been associated with prostate cancer risk, male infertility, and rheumatoid arthritis. Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3.
|
Map of ordered and disordered regions |
Note: 'Mouse' over a region to see the start and stop residues. Click on a region to see detailed information.
|
Region 1 | Type: | Disordered | Name: | AF1 domain, Amino Terminal Domain (NTD) | Location: | 142 - 485 | Length: | 344 | Region sequence: |
GLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVS EGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQL RGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGE SLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHP HARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEE GQLYGPCGGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRP | Modification type: | Engineered
Fragment
Monomeric
Native
| PDB: | | Structural/functional type: | Function arises via a disorder to order transition | Functional classes: | Modification site
Molecular recognition effectors
Molecular assembly
| Functional subclasses: | Transactivation (transcriptional activation)
Phosphorylation
Protein-protein binding
| Detection methods:
- Sensitivity to proteolysis (pH: 7.9; CaCl2 20 mM; EDTA 0.2 mM; glycerol 10 %; HEPES 25 mM; KCl 60 mM; MgCl2 5 mM)
- Fluorescence, intrinsic
- Circular dichroism (CD) spectroscopy, far-UV (293 K; dithiothreitol 1 mM; Na2HPO4 6 mM; NaH2PO4 4 mM; sodium sulfate 100 mM)
| References:
- Kumar R, Betney R, Li J, Thompson EB, McEwan IJ. "Induced alpha-helix structure in AF1 of the androgen receptor upon binding transcription factor TFIIF." Biochemistry. 2004; 43(11): 3008-13. PubMed: 15023052
- Reid J, Kelly SM, Watt K, Price NC, McEwan IJ. "Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions." J Biol Chem. 2002; 277(22): 20079-86. PubMed: 11896058
| Comments:Binding of NTD to target protein TFIIF transcription factor induces folding into a more stable conformation.
|
Region 2 | Type: | Ordered | Name: | DNA Binding Domain | Location: | 548 - 612 | Length: | 65 | Region sequence: |
PIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFR RKNCP | Modification type: | | PDB: | | Structural/functional type: | Function arises from the ordered state | Functional classes: | | Functional subclasses: | Protein-DNA binding
| Detection methods:
- X-ray crystallography
| References:
- Reid J, Kelly SM, Watt K, Price NC, McEwan IJ. "Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions." J Biol Chem. 2002; 277(22): 20079-86. PubMed: 11896058
| Comments:
|
Region 3 | Type: | Ordered | Name: | Ligand Binding Domain | Location: | 663 - 919 | Length: | 257 | Region sequence: |
HIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKAL PGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYS QCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRII ACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQ VPKILSGKVKPIYFHTQ | Modification type: | | PDB: | | Structural/functional type: | Function arises from the ordered state | Functional classes: | | Functional subclasses: | Protein-protein binding
| Detection methods:
- X-ray crystallography
| References:
- Reid J, Kelly SM, Watt K, Price NC, McEwan IJ. "Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions." J Biol Chem. 2002; 277(22): 20079-86. PubMed: 11896058
| Comments:
|
References |
- Jenster G, van der Korput HA, Trapman J, Brinkmann AO. "Identification of two transcription activation units in the N-terminal domain of the human androgen receptor." J Biol Chem. 1995; 270(13): 7341-6. PubMed: 7706276
- Simental JA, Sar M, Lane MV, French FS, Wilson EM. "Transcriptional activation and nuclear targeting signals of the human androgen receptor." J Biol Chem. 1991; 266(1): 510-8. PubMed: 1985913
|
If you have any comments or wish to provide additional references to this protein or its disordered region(s), please click here to e-mail us. |
Disprot-footer
|